SCHEMBL16615794

SCHEMBL16615794

Cc1ncc(CNC(=O)c2ccc(CNC(=O)c3ccc(Cl)cc3Cl)cn2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 3/20 0.49
GRIN1 Q05586 2/20 0.49
HPGD P15428 5/20 0.48
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
GAA P10253 1/20 0.46
POLB P06746 3/20 0.45
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 2/20 0.42
GRIN2B Q13224 1/20 0.42
MAPT P10636 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615789 0.89 GRIN2A (0.53) GRIN2AGRIN1HPGDHTTGAA
SCHEMBL16615941 0.88 GRIN2A (0.63) GRIN2AGRIN1HPGDLMNAHTT
SCHEMBL16615793 0.84 GRIN2A (0.45) GRIN2AGRIN1HPGDLMNAPOLB
SCHEMBL16615844 0.82 EPHX2 (0.51) GRIN2AGRIN1HPGDLMNAHTT
SCHEMBL16713069 0.80 GRIN2A (0.45) GRIN2AGRIN1HPGDLMNAL3MBTL1
SCHEMBL16615929 0.79 GRIN2A (0.49) GRIN2AGRIN1LMNAGAAPOLB
SCHEMBL16598124 0.79 GRIN2A (0.60) GRIN2AGRIN1LMNAHTTGAA
SCHEMBL16615806 0.78 GRIN2A (0.61) GRIN2AGRIN1HTTPOLBKMT2A
SCHEMBL16598435 0.78 GRIN2A (0.61) GRIN2AGRIN1LMNAHTTKMT2A
SCHEMBL16598153 0.77 GRIN2A (0.67) GRIN2AGRIN1HPGDHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885HPGD 3080/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885HPGD 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.